About Tonghua Dongbao Pharmaceutical Company

The company was founded in 1985 and is a famous domestic pharmaceutical manufacturer integrating drug research and development, production and sales. In August 1994, the company was listed on the Shanghai Stock Exchange. Over the years, the company has set up a scientific and technological research and development team with the development concept of “adhering to independent innovation and creating a world brand” to focus on the research and development of drugs in treatment fields such as diabetes. In 1998, China's first recombinant human insulin, “Gan Shulin,” was successfully developed, which not only filled the domestic gap, but also made China the third country in the world that can produce recombinant human insulin after the United States and Denmark. It is mainly engaged in drug research and development, production and sales. The main business covers biological products, proprietary Chinese medicines, and chemicals. The treatment fields are mainly diabetes, endocrine, and cardiovascular. The company has a series of products represented by human insulin (registered trademark: Gan Shulin), insulin glargine (registered trademark: Ping Shulin), and Mendong insulin (registered trademark: Rui Shulin). Company honors: The company has a national enterprise technology center, a national GMP and EU GMP certified production workshop. It is recognized by the country as a high-tech enterprise, a national technological innovation demonstration enterprise, and an ISO14001 environmental system certified enterprise.